Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
IGF-1 and its receptor in esophageal cancer: association with adenocarcinoma and visceral obesity.
Doyle SL, Donohoe CL, Finn SP, Howard JM, Lithander FE, Reynolds JV, Pidgeon GP, Lysaght J.
Am J Gastroenterol. 2012 Feb;107(2):196-204. doi: 10.1038/ajg.2011.417. Epub 2011 Dec 6.
Related citations
Differentiation-promoting culture of competent and noncompetent keratinocytes identifies biomarkers for head and neck cancer.
Ceder R, Haig Y, Merne M, Hansson A, Zheng X, Roberg K, Nees M, Iljin K, Bloor BK, Morgan PR, Fadeel B, Grafström RC.
Am J Pathol. 2012 Feb;180(2):457-72. Epub 2011 Dec 3.
Prognostic factors in definitive radiochemotherapy of advanced inoperable esophageal cancer.
Semrau R, Herzog SL, Vallböhmer D, Kocher M, Hölscher AH, Müller RP.
Dis Esophagus. 2011 Dec 2. doi: 10.1111/j.1442-2050.2011.01286.x. [Epub ahead of print]
Use of a posterior pedicle nasal septum and floor mucoperiosteum flap to resurface the nasopharynx after endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma.
Chen MY, Wang SL, Zhu YL, Shen GP, Qiu F, Luo DH, Chen QY, Jiang R, Cao KJ, Qian CN, Hong MH.
Head Neck. 2011 Dec 5. doi: 10.1002/hed.21928. [Epub ahead of print]
Adaptive Radiotherapy for Head-and-Neck Cancer: Initial Clinical Outcomes From a Prospective Trial.
Schwartz DL, Garden AS, Thomas J, Chen Y, Zhang Y, Lewin J, Chambers MS, Dong L.
Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):986-93. Epub 2011 Dec 2.
A Planned Neck Dissection Is Not Necessary in All Patients With N2-3 Head-and-Neck Cancer After Sequential Chemoradiotherapy.
Soltys SG, Choi CY, Fee WE, Pinto HA, Le QT.
Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):994-9. Epub 2011 Dec 2.
Management of dermatitis in patients with locally advanced squamous cell carcinoma of the head and neck receiving cetuximab and radiotherapy.
Gutiérrez LC, Khosravi-Shahi P, Alvarez YE.
Oral Oncol. 2012 Apr;48(4):293-7. Epub 2011 Dec 3.
Activation of mTOR signaling in medullary and aggressive papillary thyroid carcinomas.
Kouvaraki MA, Liakou C, Paraschi A, Dimas K, Patsouris E, Tseleni-Balafouta S, Rassidakis GZ, Moraitis D.
Surgery. 2011 Dec;150(6):1258-65.
Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study.
Sugitani I, Fujimoto Y.
Surgery. 2011 Dec;150(6):1250-7.
Anaplastic thyroid carcinoma: hope on the horizon?
Grant CS, Thompson G.
Surgery. 2011 Dec;150(6):1220-1. No abstract available.
Prospective application of our novel prognostic index in the treatment of anaplastic thyroid carcinoma.
Orita Y, Sugitani I, Amemiya T, Fujimoto Y.
Surgery. 2011 Dec;150(6):1212-9.
Preoperative basal calcitonin and tumor stage correlate with postoperative calcitonin normalization in patients undergoing initial surgical management of medullary thyroid carcinoma.
Yip DT, Hassan M, Pazaitou-Panayiotou K, Ruan DT, Gawande AA, Gaz RD, Moore FD Jr, Hodin RA, Stephen AE, Sadow PM, Daniels GH, Randolph GW, Parangi S, Lubitz CC.
Surgery. 2011 Dec;150(6):1168-77.
Prophylactic central compartment neck dissection for papillary thyroid cancer: the search for justification continues.
McHenry CR.
Surgery. 2011 Dec;150(6):1058-60. No abstract available.
Novel therapy for anaplastic thyroid carcinoma cells using an oncolytic vaccinia virus carrying the human sodium iodide symporter.
Gholami S, Haddad D, Chen CH, Chen NG, Zhang Q, Zanzonico PB, Szalay AA, Fong Y.
Surgery. 2011 Dec;150(6):1040-7.
BRAF(K601E) mutation in a patient with a follicular thyroid carcinoma.
Pennelli G, Vianello F, Barollo S, Pezzani R, Merante Boschin I, Pelizzo MR, Mantero F, Rugge M, Mian C.
Thyroid. 2011 Dec;21(12):1393-6.
Long-term outcome of comprehensive central compartment dissection in patients with recurrent/persistent papillary thyroid carcinoma.
Clayman GL, Agarwal G, Edeiken BS, Waguespack SG, Roberts DB, Sherman SI.
Thyroid. 2011 Dec;21(12):1309-16.
Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
Soyluk O, Boztepe H, Aral F, Alagol F, Özbey NC.
Thyroid. 2011 Dec;21(12):1301-8.
Association of BRCA1 functional single nucleotide polymorphisms with risk of differentiated thyroid carcinoma.
Xu L, Doan PC, Wei Q, Liu Y, Li G, Sturgis EM.
Thyroid. 2012 Jan;22(1):35-43. Epub 2011 Dec 2.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on